Core Viewpoint - Athira Pharma announced transformative transactions in a press release, which were discussed during the conference call [2][3]. Group 1: Company Overview - The conference call featured key executives including Dr. Mark Litton (President and CEO), Dr. Javier San Martin (Chief Medical Officer), Dr. Kevin Church (Chief Scientific Officer), Robert Renninger (Chief Financial Officer), and Dr. David Portman (Founder and CEO of Sermonix) [2]. Group 2: Financial and Operational Insights - The call included forward-looking statements regarding the company's future clinical development activities, financial condition, and operating performance, which are based on management's current beliefs and expectations [4].

Core Insights - Athira Pharma has secured a deal to test a promising breast cancer drug, indicating a strategic shift in its focus [1] - The company has also obtained $90 million in upfront funding from investors, which will support its research and development efforts [1] Company Developments - The deal for the breast cancer drug represents a significant pivot for Athira Pharma, suggesting a potential expansion of its therapeutic portfolio [1] - The $90 million funding is a crucial financial boost that will enable the company to advance its clinical trials and further its drug development initiatives [1]

Core Viewpoint - Athira Pharma, Inc. announced an agreement to acquire global development and commercialization rights to lasofoxifene, a Phase 3 ready asset for metastatic breast cancer, leading to a significant surge in its stock price [1] Group 1: Stock Performance - Athira Pharma shares surged 69.53 percent, gaining $2.88 to trade at $7.01 on Thursday [1] - The stock opened at $7.22 and fluctuated within a day's range of $6.77 to $8.35 [2] - Trading volume spiked to approximately 53.19 million shares, significantly higher than the average volume of around 30,063 shares [2] Group 2: Market Reaction - Investors reacted positively to the late-stage pipeline expansion, with shares now trading near the top of its 52-week range of $2.20 to $8.35 [2]

Market Overview - U.S. stocks experienced a significant rebound, driven by softer-than-expected inflation data and strong corporate earnings, particularly from Micron Technology [1][2][17] - Major indexes, including the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite, posted solid gains, with the Nasdaq leading the advance [4][17] Inflation Data - The November Consumer Price Index (CPI) reported annual headline inflation at 2.7%, significantly below the Dow Jones estimate of 3.1%, while core CPI was at 2.6%, compared to an expected 3% [6][15] - The report was delayed due to a government shutdown and lacked month-over-month comparisons, but markets reacted positively to the lower annual inflation readings [7][17] Corporate Earnings - Micron Technology's shares surged approximately 15% after the company exceeded Wall Street estimates for revenue and earnings in its fiscal first quarter, citing improving demand for AI-related memory chips [11][16] - The positive performance of Micron helped stabilize the broader semiconductor sector, which had faced recent declines [12][16] Sector Performance - Despite recent volatility, the technology sector remains one of the strongest performers of the year, projected to end 2025 with gains of around 20% [5][17] - Other major chipmakers, including Broadcom, Nvidia, and AMD, faced pressure due to concerns over rising capital costs tied to large-scale data center investments, but long-term optimism remains intact [13][14] Labor Market Signals - Initial jobless claims came in below expectations, reinforcing the view that the U.S. economy remains stable despite higher interest rates [8][17]

Market Performance - U.S. stocks experienced a positive trading session, with the Dow Jones index increasing by approximately 400 points, up 0.84% to 48,289.58, while the NASDAQ rose 1.53% to 23,040.25, and the S&P 500 gained 1.09% to 6,794.36 [1] - Consumer discretionary shares increased by 1.6%, while energy stocks fell by 0.8% [1] Company Earnings - Accenture reported first-quarter 2026 earnings of $3.94 per share, exceeding the analyst consensus estimate of $3.75, and sales of $18.700 billion, slightly above the consensus estimate of $18.523 billion [2] Commodity Prices - Oil prices rose by 1% to $56.48, while gold prices decreased by 0.2% to $4,364.50. Silver fell by 1.1% to $66.160, and copper increased by 0.1% to $5.4370 [5] European Market Performance - European shares showed gains, with the eurozone's STOXX 600 up 0.5%, Spain's IBEX 35 Index rising 0.7%, London's FTSE 100 gaining 0.1%, Germany's DAX 40 increasing by 0.5%, and France's CAC 40 up 0.4% [6] Asian Market Performance - Asian markets closed mixed, with Japan's Nikkei down 1.03%, Hong Kong's Hang Seng up 0.12%, China's Shanghai Composite rising 0.16%, and India's BSE Sensex falling 0.09% [7] Stock Movements - Athira Pharma Inc shares surged 88% to $7.76 following an agreement to acquire rights for lasofoxifene development. Sable Offshore Corp shares increased by 58% to $8.36, and FuelCell Energy Inc shares rose by 32% to $10.39 after reporting better-than-expected fourth-quarter results [9] - Conversely, Mega Fortune Co Ltd shares dropped 59% to $5.34, and Pyxis Oncology Inc shares fell 54% to $1.56 after announcing preliminary data from clinical studies. Actelis Networks Inc shares decreased by 45% to $0.60 following a public offering announcement [9]

Summary of Athira Pharma Conference Call - December 18, 2025 Company Overview - **Company**: Athira Pharma (NasdaqGS:ATHA) - **Focus**: Development of innovative therapies for diseases with unmet medical needs, specifically in oncology and neurology Key Points Discussed Transformative Acquisition - Athira announced the acquisition of rights to develop and commercialize **lasofoxifene**, a potential treatment for metastatic breast cancer, which diversifies its pipeline with a late-stage program [5][15][16] - The acquisition is expected to enhance Athira's mission to deliver transformative therapies for patients [5][14] Lasofoxifene Overview - Lasofoxifene is currently in a pivotal phase III clinical trial targeting **ER-positive HER2-negative metastatic breast cancer**, which represents about 70% of all breast cancer cases [15][16] - The global market for metastatic ER-positive HER2-negative breast cancer is projected to grow from **$10.9 billion in 2025 to over $15.9 billion by 2029** [15] - Lasofoxifene has shown promising clinical activity, achieving **13 months of progression-free survival (PFS)** in combination therapy during phase II trials [20][26] Clinical Data and Mechanism - Lasofoxifene demonstrated an **83% reduction in new-onset primary wild-type estrogen receptor-positive breast cancer** in previous studies [19] - It modulates the estrogen receptor rather than degrading it, providing tissue selectivity and sparing healthy estrogen receptors in critical tissues [19][21] - The drug has shown **significant efficacy against ESR1 mutations**, which occur in over 40% of patients and are a major mechanism of resistance in breast cancer treatments [20][21] ATH-1105 for ALS - Athira is also advancing **ATH-1105**, a potential treatment for **Amyotrophic Lateral Sclerosis (ALS)**, which affects approximately **33,000 patients in the U.S.** [37] - ATH-1105 modulates the hepatocyte growth factor (HGF) system, which is critical for neuronal health [38] - Preclinical studies have shown that ATH-1105 preserves motor function and reduces neurodegeneration in ALS models [39][40] Financial and Strategic Positioning - Athira raised **$90 million** to support its development programs, with the potential for an additional **$146 million** through warrants [46] - The financing positions the company to reach critical data readouts across both programs by the end of **2027** [46] - Athira aims to achieve peak annual U.S. sales for lasofoxifene approaching **$1 billion** if approved [35] Market Opportunity - The global breast cancer market is approximately **$55 billion**, with the second-line breast cancer segment in the U.S. exceeding **$5-$6 billion annually** [34] - Lasofoxifene's favorable tolerability profile and unique attributes position it as a potential leading therapy in this market [35][36] Conclusion - Athira is committed to advancing its promising development programs for lasofoxifene and ATH-1105, addressing significant unmet needs in metastatic breast cancer and ALS [45] - The company is optimistic about its future and the potential impact of its therapies on patient outcomes [47]

Lasofoxifene (Metastatic Breast Cancer) - The global metastatic ER+/HER2- breast cancer market is expected to grow from approximately $10.9 billion in 2025 to roughly $15.9 billion by 2029[23] - Lasofoxifene, combined with abemaciclib, demonstrated a potential best-in-class median Progression-Free Survival (PFS) of 13 months in a heavily pre-treated mESR1 population in the Phase 2 ELAINE-2 trial[26, 27, 50] - In the ELAINE-1 Phase 2 study, lasofoxifene delivered a median PFS of 24.2 weeks compared to 16.2 weeks with fulvestrant in ESR1-mutant breast cancer[48] - Approximately 70% of all breast cancers are ER+/HER2- subtype[23, 32] - Lasofoxifene reduced new onset breast cancer by 83% in a large prevention trial[30] - The ELAINE-3 registrational Phase 3 trial is ongoing, with topline results expected in mid-2027 and over 50% enrollment[16, 17, 57, 138, 139] - Assuming approximately 10% market penetration, lasofoxifene has a peak market sale potential of over $1 billion in the US market[81] ATH-1105 (ALS) - Approximately 225,000 people globally are affected by ALS, with roughly 33,000 cases in the US[98] - ATH-1105 is a CNS-penetrant positive modulator of HGF as a potential treatment for ALS[103] - A Phase 2 POC study in ALS is planned to start in the first half of 2026, with topline results expected in 2027[18, 19, 140, 141] Financial - A PIPE financing of up to $236 million, including $90 million upfront, provides cash runway through data readout and into 2028[137]

Core Viewpoint - Athira Pharma has acquired the rights to develop and commercialize lasofoxifene, a selective estrogen receptor modulator (SERM), for the treatment of metastatic breast cancer, representing a significant opportunity in a multi-billion dollar market [2][3][4]. Financing and Development - Athira announced a $90 million upfront financing through private placement, co-led by Commodore Capital, Perceptive Advisors, and TCGX, with potential additional funding of up to $146 million through warrants [4][9]. - The financing aims to support the development of lasofoxifene through key clinical and regulatory milestones, with sufficient capital projected to last into 2028 [4][9]. Clinical Trials and Data - The ongoing Phase 3 ELAINE-3 clinical trial is over 50% enrolled, with pivotal data expected in mid-2027 [2][19]. - Previous Phase 2 trials (ELAINE-1 and ELAINE-2) demonstrated lasofoxifene's potential, showing significant progression-free survival and objective response rates in heavily pre-treated patients [17][18]. Market Opportunity - The metastatic breast cancer treatment market is projected to grow from $17.1 billion in 2021 to $41.7 billion by 2030, with a compound annual growth rate (CAGR) of approximately 10.4% [14][15]. - Approximately 40% of breast cancer patients develop ESR1 mutations, creating a substantial market for lasofoxifene as a preferred endocrine therapy [5][14]. License Agreement Details - Athira has entered into a license agreement with Sermonix Pharmaceuticals, which includes a pre-funded warrant for approximately 5.5 million shares and potential milestone payments of up to $100 million based on commercialization success [6][9]. Company Overview - Athira Pharma is focused on developing novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and neurodegenerative diseases [23].

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES WHITE ROCK, BRITISH COLUMBIA / ACCESS Newswire / December 15, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") is pleased to announce that, further to its news releases of November 17, November 24 and December 9, 2025, the Company has closed the second tranche of its private placement financing ...

Core Viewpoint - Athena Gold Corporation has successfully closed the first tranche of a non-brokered private placement, raising a total of CDN $2,727,526.03 out of a targeted CDN $3,100,000 [1] Fundraising Details - The first tranche includes CDN $1,331,801.03 raised through the issuance of 19,025,729 flow-through units at a price of CDN $0.07 per unit [1] - An additional CDN $1,015,500.08 was raised through the issuance of 14,507,144 flow-through common shares at the same price of CDN $0.07 per share [1] - Lastly, CDN $380,224.92 was raised through the issuance of 6,337,082 non-flow-through units at a price of CDN $0.06 per unit [1]